APGE — APOGEE THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About APOGEE THERAPEUTICS INC (APGE)
APOGEE THERAPEUTICS INC (APGE) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $60M. Across recent filings, tracked investors recorded 5 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in APGE
How many top investors track APGE
A small number of top investors own this.
APGE Ownership Composition
How APOGEE THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Other98.2%
- Hedge Funds1.8%
Tracked investors reporting APGE
- Ken GriffinMar 31, 2026Citadel AdvisorsShares652.6KValue$54.9M% Portfolio0.01%
- Izzy EnglanderMar 31, 2026Millennium ManagementShares92.6KValue$7.8M% Portfolio0.00%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares13.8KValue$1.2M% Portfolio0.00%
Recent activity
- $10.6MFeb 17, 2026
- $7.8MMay 15, 2026
- New$54.9MMay 15, 2026
- New$1.2MMay 15, 2026
- New$47.6MNov 14, 2025
Frequently asked questions
- How many institutional investors hold APGE?
- 3 tracked institutional investors disclosed a position in APGE (APOGEE THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of APGE?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in APGE, valued at $60M.
- Did institutional ownership of APGE increase or decrease?
- Across recent 13F filings, tracked investors recorded 5 new positions, 0 increased, 0 reduced, and 0 fully exited APGE.
- Where does this APGE ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.